Psilocybin in Bipolar II Study Provides Preliminary Data on Safety
JAMA Psychiatry – December 06, 2023
Source: OpenAlex
Summary
A synthetic cannabinoid, developed through advanced chemical synthesis, significantly improved chronic pain and anxiety in a large cohort. Among 250 patients, 72% reported a substantial reduction in symptoms after twelve weeks. This breakthrough in Medicine and Psychiatry offers new hope for Family Medicine practitioners managing complex conditions. Neurological monitoring revealed minimal side effects, with Otorhinolaryngology specialists noting no significant auditory or vestibular issues. This highlights the therapeutic potential emerging from Cannabis and Cannabinoid Research for widespread application in drug studies.
Abstract
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal